Belen Perez Solans, PhD
Postdoctoral Scholar
Bioengineering
School of Pharmacy

Publications (14)

Top publication keywords:
Heterocyclic Compounds, 3-RingTuberculosisClofazimineLevofloxacinLinezolidAnemiaOxazinesTuberculosis, Multidrug-ResistantAntitubercular AgentsDiarylquinolinesIsoniazidMycobacterium tuberculosisOxazolidinonesRifampinOrthopedic Procedures

• Pharmacokinetics and Dose Optimization of Ethambutol in Children on First-line Antituberculosis Therapy: An Individual Patient Data Meta-Analysis.
  The Journal of infectious diseases 2026 Chung TK, Yang E, Shin M, Solans BP, Zhou X, Hwang S, Yoon MC, Purohit D, Yang D, Mouksassi S, Béranger A, Bekker A, Kwara A, Panjasawatwong N, Savic RM
• Efficacy of isoniazid in paediatric tuberculosis: an individual participant data meta-analysis.
  The European respiratory journal 2026 Béranger A, Solans BP, Miyakawa R, McIlleron H, Tarning J, Shah I, Aruldhas BW, Mathew BS, Kwara A, Peloquin CA, Mukherjee A, Lodha R, Denti P, Capparelli EV, Kiser JJ, Bekker A, Chabala C, Choo L, …
• Dolutegravir concentrations in children receiving 3-month weekly isoniazid and rifapentine (3HP) for tuberculosis prevention.
  Microbiology spectrum 2026 Madzime RJ, van der Laan L, du Toit S, Barnabas S, Courtney I, Brown NE, Savic R, Solans BP, Dixon MG, Tsirizani L, Denti P, Boyd R, Hesseling AC, TBTC Study 35 team
• Deriving Dosages for Levofloxacin Tuberculosis Preventive Treatment for Young People Exposed to Rifampicin-Resistant Tuberculosis.
  The Journal of infectious diseases 2025 Solans BP, Miyakawa R, Shin M, Hesseling AC, White Y, Masini T, Kanchar A, Falzon D, Savic RM
• Pharmacokinetics and Safety of Clofazimine in Children With Rifampicin-Resistant Tuberculosis.
  The Journal of infectious diseases 2025 Hughes JA, Solans BP, Garcia-Prats AJ, Draper HR, Schaaf HS, Nielsen JC, Nortier E, Courtney I, Palmer M, van der Laan L, Savic RM, Hesseling AC

Show all (9 more) Hide

• Simultaneous initiation of dolutegravir-based antiretroviral therapy and once-weekly rifapentine and isoniazid for tuberculosis prevention in antiretroviral-naive people with HIV: an open-label, non-randomised, phase 1/2 trial.
  The lancet. HIV 2025 Weld ED, Beattie T, Moodley J, Mapendere M, Salles I, Solans BP, Nonyane BAS, Wiesner L, Nielson T, Edward VA, Chihota V, Savic RM, Dooley KE, Chaisson RE, Churchyard GJ, DOLPHIN-TOO Study Team, …
• Characteristics of children and adolescents with multidrug-resistant and rifampicin-resistant tuberculosis and their association with treatment outcomes: a systematic review and individual participant data meta-analysis.
  The Lancet. Child & adolescent health 2025 Garcia-Prats AJ, Garcia-Cremades M, Cox V, Kredo T, Dunbar R, Schaaf HS, Seddon JA, Furin J, Achar J, Radke K, Sachs T, Abubakirov A, Ahmed S, Akkerman OW, Al Ani NA, Amanullah F, Ahmad N, Anderson LF…
• Linezolid Pharmacokinetic-Anemia Modeling in Children With Rifampicin-Resistant Tuberculosis.
  Clinical infectious diseases : an official publication of the Infectious Diseases Society of America 2024 Brooks JT, Solans BP, Béranger A, Schaaf HS, van der Laan L, Sharma S, Furin J, Draper HR, Hesseling AC, Garcia-Prats AJ, Savic RM
• Optimizing Lumefantrine Dosing for Young Children in High-Malaria-Burden Countries Using Pharmacokinetic-Pharmacodynamic Simulations.
  Open forum infectious diseases 2024 Simeon S, Hughes E, Wallender E, P Solans B, Savic R
• Dose optimization of TBI-223 for enhanced therapeutic benefit compared to linezolid in antituberculosis regimen.
  Nature communications 2024 Strydom N, Ernest JP, Imperial M, Solans BP, Wang Q, Tasneen R, Tyagi S, Soni H, Garcia A, Bigelow K, Gengenbacher M, Zimmerman M, Xie M, Sarathy JP, Yang TJ, Dartois V, Nuermberger EL, Savic RM
• Pharmacokinetic-pharmacodynamic modeling of tuberculosis time to positivity and colony-forming unit to assess the response to dose-ranging linezolid.
  Antimicrobial agents and chemotherapy 2024 Simeon S, Garcia-Cremades M, Savic R, Solans BP
• Prolonged Opioid Use Is Associated With Poor Pain Alleviation After Orthopaedic Surgery.
  The Journal of the American Academy of Orthopaedic Surgeons 2024 Marmor MT, Hu S, Mahadevan V, Floren A, Solans BP, Savic R
• Pharmacokinetics and Optimal Dosing of Levofloxacin in Children for Drug-Resistant Tuberculosis: An Individual Patient Data Meta-Analysis.
  Clinical infectious diseases : an official publication of the Infectious Diseases Society of America 2024 White YN, Solans BP, Denti P, van der Laan LE, Schaaf HS, Vonasek B, Malik AA, Draper HR, Hussain H, Hesseling AC, Garcia-Prats AJ, Savic RM
• Pharmacokinetics and cardiac safety of clofazimine in children with rifampicin-resistant tuberculosis.
  Antimicrobial agents and chemotherapy 2023 Ali AM, P Solans B, Hesseling AC, Winckler J, Schaaf HS, Draper HR, van der Laan L, Hughes J, Fourie B, Nielsen J, Wiesner L, Garcia-Prats AJ, Savic RM